C R Meier

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus
    C R Meier
    Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA 02173, USA
    J Rheumatol 25:1515-9. 1998
  2. ncbi Antibiotics and risk of subsequent first-time acute myocardial infarction
    C R Meier
    Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, Mass 02421, USA
    JAMA 281:427-31. 1999
  3. ncbi Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer
    C R Meier
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Mass, USA
    Arch Intern Med 160:349-53. 2000
  4. ncbi Statin use, hyperlipidaemia, and the risk of breast cancer
    J A Kaye
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Br J Cancer 86:1436-9. 2002
  5. ncbi Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma
    M R Nowrousian
    Department of Internal Medicine (Cancer Research, West German Tumor Centre, University of Essen
    Acta Oncol 28:495-500. 1989
  6. ncbi Risk of cataract in patients treated with statins
    R G Schlienger
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital of Basel, Switzerland
    Arch Intern Med 161:2021-6. 2001
  7. ncbi Migraine incidence, comorbidity and health resource utilization in the UK
    C Becker
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
    Cephalalgia 28:57-64. 2008
  8. ncbi Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study
    Y B Brauchli
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, 4031 Basel, Switzerland
    Br J Dermatol 158:1299-307. 2008

Collaborators

Detail Information

Publications8

  1. ncbi Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus
    C R Meier
    Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA 02173, USA
    J Rheumatol 25:1515-9. 1998
    ..We examined the association of postmenopausal estrogen use with the development of SLE and discoid lupus...
  2. ncbi Antibiotics and risk of subsequent first-time acute myocardial infarction
    C R Meier
    Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, Mass 02421, USA
    JAMA 281:427-31. 1999
    ..If such a causal association exists, subjects who used antibiotics active against the bacteria, regardless of indication, might be at lower risk of developing acute myocardial infarction than nonusers...
  3. ncbi Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer
    C R Meier
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Mass, USA
    Arch Intern Med 160:349-53. 2000
    ....
  4. ncbi Statin use, hyperlipidaemia, and the risk of breast cancer
    J A Kaye
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Br J Cancer 86:1436-9. 2002
    ..8; 95% confidence interval 0.9-3.4). We found no evidence for an increasing trend in breast cancer risk with increasing duration of statin use (median duration 1.8 years, maximum 8.6 years)...
  5. ncbi Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma
    M R Nowrousian
    Department of Internal Medicine (Cancer Research, West German Tumor Centre, University of Essen
    Acta Oncol 28:495-500. 1989
    ..The value of this program, however, can only be established comparing it with other newly developed protocols in randomized studies...
  6. ncbi Risk of cataract in patients treated with statins
    R G Schlienger
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital of Basel, Switzerland
    Arch Intern Med 161:2021-6. 2001
    ..2-4.1). CONCLUSIONS: Our study provides evidence that long-term use of therapeutic statin doses does not increase the risk of developing cataract. Concomitant use of erythromycin and simvastatin may increase the cataract risk...
  7. ncbi Migraine incidence, comorbidity and health resource utilization in the UK
    C Becker
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
    Cephalalgia 28:57-64. 2008
    ..This study shows that migraine is a common diagnosis in general practice and associated with a high prevalence of comorbidity. The increased HRU in triptan users suggests greater migraine severity...
  8. ncbi Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study
    Y B Brauchli
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, 4031 Basel, Switzerland
    Br J Dermatol 158:1299-307. 2008
    ..Several case reports have associated use of beta-blockers with an increased risk of psoriasis or psoriasiform drug eruptions...